Last edition
News about "cancer immunotherapy"
Ichnos Glenmark Innovation Unveils Novel Multispecific Antibody Candidate for Solid Tumour Treatment
Ichnos Glenmark Innovation has introduced ISB 2301, a next-generation multispecific antibody designed to activate immune cells and target solid tumours through a multi-mechanism approach aimed at improving cancer treatment outcomes.
Cancer Immunotherapy | 22/05/2026 | By News Bureau
Harbour BioMed Secures FDA IND Clearance for HBM7004 in Advanced Solid Tumors
Harbour BioMed receives US Food and Drug Administration (FDA) IND clearance for HBM7004, a novel B7H4xCD3 bispecific antibody developed on its HBICE platform for advanced solid tumors.
Cancer Immunotherapy | 11/05/2026 | By News Bureau
FDA Grants Priority Review to Astellas and Pfizer's Bladder Cancer Combination Therapy
Astellas and Pfizer’s Padcev-Keytruda combination moves closer to expanded approval, offering a potential new treatment option to reduce recurrence and improve survival in bladder cancer patients.
Cancer Immunotherapy | 21/04/2026 | By News Bureau
OS Therapies files patent for immune-response biomarker linked to cancer immunotherapy
New data from the Phase IIb trial of OST-HER2 shows distinct immune signatures tied to improved survival outcomes, supporting accelerated approval discussions with global regulators.
Cancer Immunotherapy | 20/04/2026 | By News Bureau
Cbio A/S has received regulatory approval to begin a Phase I/IIa trial of novoleucel, a next-generation T-cell therapy, in patients with recurrent Cervical Cancer.
Cancer Immunotherapy | 16/03/2026 | By News Bureau | 123
Oricell Therapeutics Raises USD 70M in Series C1 to Advance CAR-T Therapies for Solid Tumors
The funding will accelerate global expansion and clinical development of Oricell’s CAR-T pipeline, including its lead hepatocellular carcinoma programme Ori-C101.
Cancer Immunotherapy | 13/01/2026 | By News Bureau | 254
FDA Grants ODD to Leukogene Therapeutics' M2T-CD33 (LTI-214) for Treating Acute Myeloid Leukemia
The US FDA has granted ODD to Leukogene Therapeutics’ M2T-CD33 (LTI-214) for the treatment of Acute Myeloid Leukemia (AML). The designation highlights the pressing need for new treatment options and acknowledges LTI-214’s potential as a novel and targeted therapy for this aggressive form of blood cancer.
Cancer Immunotherapy | 05/11/2025 | By Dineshwori | 255
TuHURA Biosciences Signs Exclusivity and Right of First Offer Deal for Kineta
TuHURA Biosciences, Inc. has entered into an Exclusivity and Right of First Offer Agreement with Kineta, Inc. for the potential acquisition of Kineta's KVA12123 anti-VISTA antibody and related rights and assets associated with and derived from the asset.
Cancer Immunotherapy | 09/07/2024 | By Aishwarya | 630
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy